Department of Neurology, Huntington Center North Rhine-Westphalia, Ruhr-University Bochum, St. Josef-Hospital Bochum, Gudrunstraße 56, 44791, Bochum, Germany.
J Neurol. 2022 Sep;269(9):5144-5150. doi: 10.1007/s00415-022-11196-7. Epub 2022 May 28.
The phosphodiesterase-5 inhibitor sildenafil was postulated to reduce the risk for Alzheimer's Disease. Since preclinical data revealed beneficial effects in Huntington's Disease (HD), we now for the first time investigated effects of sildenafil in HD patients using the database ENROLL-HD. We demonstrate beneficial effects on motoric, functional and cognitive capacities in cross-sectional data. Those effects were not explained by underlying fundamental molecular genetic or demographic data. It remains unsolved, if effects are due to behavioral differences or due to direct dose-dependent neurobiological modulations.
磷酸二酯酶-5 抑制剂西地那非被认为可以降低阿尔茨海默病的风险。由于临床前数据显示其在亨廷顿病（HD）中有有益作用，我们现在首次使用 ENROLL-HD 数据库研究了西地那非在 HD 患者中的作用。我们在横断面数据中证明了对运动、功能和认知能力的有益影响。这些影响不能用潜在的基本分子遗传或人口统计学数据来解释。其作用是由于行为差异还是由于直接的剂量依赖性神经生物学调节仍未解决。
